Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes Among Patients with Myelodysplastic Syndromes Treated with Iron Chelation Therapy: A Real World Medicare Database Study

Yanni Hao, PhD, Alex Z Fu, PhD, Austin Coe, Ying Qiu, PhD, Zhiyi Li, Becky Hanna, Jackson Tang, Brian M. Elliott, MD, Carole Paley, MD

Blood (2016) 128 (22): 2396.

https://doi.org/10.1182/blood.V128.22.2396.2396

Published: 2016

Journal Articles

Treatment Patterns and Adherence Among Patients with Myelodysplastic Syndromes Receiving Deferasirox As Iron Chelation Therapy: A Real World Medicare Database Study

Alex Z Fu, PhD, Yanni Hao, PhD, Austin Coe, Ying Qiu, PhD, Zhiyi Li, Becky Hanna, Jackson Tang, Brian M. Elliott, MD, Carole Paley, MD

Blood (2016) 128 (22): 4759.

https://doi.org/10.1182/blood.V128.22.4759.4759

Published: 2016

Journal Articles

Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States

Elliott P. Vichinsky, MD, Janet Kwiatkowski, MD, Patricia J. Giardina, MD, Carole Paley, MD, Francis Vekeman, MA, Wendy Y. Cheng, MPH, MPhil, Joseph Damron, BA, Nora McCormick, MSc, Medha Sasane, PhDBPharm,MS, Ying Qiu, PhD, Mei Sheng Duh, MPH, ScD, Alexis A. Thompson, MD

Blood (2015) 126 (23): 3279.

https://doi.org/10.1182/blood.V126.23.3279.3279

Published: 2015

Journal Articles

Adherence to Iron Chelation Therapy and Associated Healthcare Resource Utilization and Costs in Medicaid Patients with Sickle Cell Disease

Francis Vekeman, MA, Medha Sasane, BPharm, PhD, Wendy Y Cheng, MPH, MPhil, Agnihotram V Ramanakumar, PhD, Jonathan Fortier, MA, Mei S. Duh, ScD, MPH, Carole Paley, MD, Patricia Adams-Graves, MD

Blood (2014) 124 (21): 2177.

https://doi.org/10.1182/blood.V124.21.2177.2177

Published: 2014

Journal Articles

Comparison of Real-World Treatment Patterns and Clinical Outcomes in 18-59 Year-Old Patients with FLT3 Mutated Vs. FLT3 Wild Type Acute Myeloid Leukemia: A Medical Records Review

Jipan Xie, MD PhD, Emily Goldmann, MPH, PhD, Anuja Roy, PhD MBA, Chelsey Yang, BA, Eric Q Wu, PhD, Carole Paley, MD

Blood (2014) 124 (21): 5992.

https://doi.org/10.1182/blood.V124.21.5992.5992

Published: 2014

Journal Articles

Relationship Between Chelation and Clinical Outcomes in Lower-Risk Patients with Myelodysplastic Syndrome (MDS): Registry Analysis at 5 Years

Roger M. Lyons, MD, Billie J. Marek, MD, Carole Paley, MD, Jason Esposito, MSHS, Katie McNamara, MSHS, CCRA, Lawrence Garbo, MD, Nicholas DiBella, MD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 1350.

https://doi.org/10.1182/blood.V124.21.1350.1350

Published: 2014

Journal Articles

Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial

Matthew M. Heeney, MD FRCP(C), Brad Baltz, MD, Patricia Adams-Graves, MD, Elizabeth Yang, MD PhD, Carole Paley, MD, Jason Esposito, MSHS, Katie McNamara, MSHS, CCRA, Elliott Vichinsky, MD, Alex George, MD, PhD

Blood (2014) 124 (21): 4890.

https://doi.org/10.1182/blood.V124.21.4890.4890

Published: 2014

Journal Articles

Pituitary Iron and Volume Are Affecting Hormones and Reproductive Potential

Sylvia T Singer, MD, Jerry Wang, MD, Qing Yuan, PhD, Elliott Vichinsky, MD, James Smith, MD, Carole Paley, MD, Roland Fischer, PhD

Blood (2014) 124 (21): 4048.

https://doi.org/10.1182/blood.V124.21.4048.4048

Published: 2014

Journal Articles

Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Matthew M Heeney, MD, Brigitta U. Mueller, MD, Brad Baltz, MD, Patricia Adams-Graves, MD, Elizabeth Yang, MD, PhD, Carole Paley, MD, Jason Esposito MSHS, McNamara Katie MSHS CCRA, Elliott Vichinsky, MD

Blood (2013) 122 (21): 988.

https://doi.org/10.1182/blood.V122.21.988.988

Published: 2013

Journal Articles

Medical Complications In Patients With Myelofibrosis By Frequency Of Blood Transfusion and Iron Chelation Therapy

Francis Vekeman, MA, Wendy Y Cheng, MPH, MPhil, Medha Sasane, BPharm, PhD, Lynn Huynh, MPH, MBA, DrPH, Michael Kaminsky, BA, Mei S. Duh, ScD, MPH, Carole Paley, MD, Ruben A. Mesa, MD

Blood (2013) 122 (21): 2964.

https://doi.org/10.1182/blood.V122.21.2964.2964

Published: 2013

Journal Articles

Utilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D.

Amer M. Zeidan, MD, Maria R. Baer, M.D., Steven D. Gore, MD, Medha Sasane, BPharm, PhD, Carole Paley, MD, Diane L. McNally, BSPharm, M.S., Amy J. Davidoff, M.S., Ph.D.

Blood (2012) 120 (21): 3178.

https://doi.org/10.1182/blood.V120.21.3178.3178

Published: 2012

Journal Articles

Age-Related Emergency Department Reliance and Healthcare Resource Utilization in Patients with Sickle Cell Disease

Morey A. Blinder, MD, Francis Vekeman, MA, Medha Sasane, BPharm, PhD, Alex Trahey, BS, Carole Paley, MD, Matthew Magestro, MBA, MS, Mei S. Duh, ScD, MPH

Blood (2012) 120 (21): 475.

https://doi.org/10.1182/blood.V120.21.475.475

Published: 2012

Journal Articles

Changes in Pituitary Iron, Volume, and Function Over Two Years in Pediatric Patients Treated with Deferasirox

John C Wood, MD, Ph.D, Leila Noetzli, BS, Ashok Panigrahy, MD, Carole Paley, MD, Ani Dongelyan, BA, Tatiana Hernandez, BA, CCRP, Vasilios Berdoukas, MB, BS, Thomas D. Coates, MD

Blood (2012) 120 (21): 3206.

https://doi.org/10.1182/blood.V120.21.3206.3206

Published: 2012

Journal Articles

PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma

Paul G. Richardson, MD, Melissa Alsina, MD, Donna Weber, MD, Steven E. Coutre, MD, Sagar Lonial, MD, Cristina Gasparetto, MD, Sutapa Mukhopadhyay, PhD, Michael Ondovik, PharmD, MBA, Mahmudul Khan, PhD, Carole Paley, MD, Robert Schlossman, MD

Blood (2012) 120 (21): 1852.

https://doi.org/10.1182/blood.V120.21.1852.1852

Published: 2012

Journal Articles

12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Matthew M. Heeney, MD, Brigitta U. Mueller, MD, Brad Baltz, MD, Patricia Adams-Graves, MD, Elizabeth Yang, MD, PhD, Carole Paley, MD, Jason Esposito, MSHS, Elliott P. Vichinsky, MD

Blood (2012) 120 (21): 1010.

https://doi.org/10.1182/blood.V120.21.1010.1010

Published: 2012

Journal Articles

Relationship Between Chelation and Clinical Outcomes in 600 Lower-Risk MDS Patients: Registry Analysis At 36 Months

Roger M. Lyons, MD, Billie J. Marek, MD, Carole Paley, MD, Jason Esposito, MSHS, Lawrence Garbo, MD, Nicholas DiBella, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3800.

https://doi.org/10.1182/blood.V120.21.3800.3800

Published: 2012

Journal Articles

Deferasirox Is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic Syndromes

Amer M. Zeidan, MD, Franklin Hendrick, B.S., Erika Friedmann, PhD, Steven D. Gore, MD, Maria R. Baer, M.D., Medha Sasane, BPharm, PhD, Carole Paley, MD, Diane L. McNally, BSPharm, M.S., Amy J. Davidoff, M.S., Ph.D.

Blood (2012) 120 (21): 426.

https://doi.org/10.1182/blood.V120.21.426.426

Published: 2012

Journal Articles

Serum Ferritin in Children with Sickle Cell Disease on Chronic Transfusion: Measure of Iron Overload or End Organ Injury? STOP/STOP II Liver Iron Ancillary Study.

Tom Adamkiewicz, MD, Miguel R. Abboud, MD, Julio C. Barredo, MD, Melanie Kirby-Allen, MD, Ofelia A. Alvarez, MD, James F. Casella, MD, Rathi V. Iyer, MD, Virgil McKie, MD, Gerald Milton Woods, MD, Abdullah Kutlar, MD, Carole Paley, MD, Jessica Peterson, Elizabeth Rackoff, Manuela Merelles-Pulcini, Elizabeth Dackiw, Kristin Stegenga, Nadine Odo, Mimi Lou, Robert J. Adams, MD

Blood (2006) 108 (11): 791.

https://doi.org/10.1182/blood.V108.11.791.791

Published: 2006

NARROW

Clinical Outcomes Among Patients with Myelodysplastic Syndromes Treated with Iron Chelation Therapy: A Real World Medicare Database Study

Treatment Patterns and Adherence Among Patients with Myelodysplastic Syndromes Receiving Deferasirox As Iron Chelation Therapy: A Real World Medicare Database Study

Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States

Adherence to Iron Chelation Therapy and Associated Healthcare Resource Utilization and Costs in Medicaid Patients with Sickle Cell Disease

Comparison of Real-World Treatment Patterns and Clinical Outcomes in 18-59 Year-Old Patients with FLT3 Mutated Vs. FLT3 Wild Type Acute Myeloid Leukemia: A Medical Records Review

Relationship Between Chelation and Clinical Outcomes in Lower-Risk Patients with Myelodysplastic Syndrome (MDS): Registry Analysis at 5 Years

Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial

Pituitary Iron and Volume Are Affecting Hormones and Reproductive Potential

Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Medical Complications In Patients With Myelofibrosis By Frequency Of Blood Transfusion and Iron Chelation Therapy

Utilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D.

Age-Related Emergency Department Reliance and Healthcare Resource Utilization in Patients with Sickle Cell Disease

Changes in Pituitary Iron, Volume, and Function Over Two Years in Pediatric Patients Treated with Deferasirox

PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma

12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Relationship Between Chelation and Clinical Outcomes in 600 Lower-Risk MDS Patients: Registry Analysis At 36 Months

Deferasirox Is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic Syndromes

Serum Ferritin in Children with Sickle Cell Disease on Chronic Transfusion: Measure of Iron Overload or End Organ Injury? STOP/STOP II Liver Iron Ancillary Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only